Advertisement
Screener

KYNTRA BIO, INC. (KYNB) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

KYNTRA BIO, INC. Research and Development Expense

KYNTRA BIO, INC. (KYNB) reported Research and Development Expense of $6.82 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13

  • KYNTRA BIO, INC. research and development expense for the quarter ending 2026-06-30 was $6.82M, a 16.30% increase year-over-year.
  • KYNTRA BIO, INC. research and development expense for the quarter ending 2026-03-31 was $7.57M, a 17.54% decline year-over-year.
  • KYNTRA BIO, INC. research and development expense for the quarter ending 2025-12-31 was $7.27M, a 5.82% increase year-over-year.
  • KYNTRA BIO, INC. research and development expense for the quarter ending 2025-09-30 was $1.21M, a 93.95% decline year-over-year.
  • KYNTRA BIO, INC. research and development expense for fiscal 2025 was $23.52M, a 75.42% decline from fiscal 2024.
  • KYNTRA BIO, INC. research and development expense for fiscal 2024 was $95.69M, a 64.09% decline from fiscal 2023.
  • KYNTRA BIO, INC. research and development expense for fiscal 2023 was $266.47M, a 10.22% decline from fiscal 2022.
  • KYNTRA BIO, INC. research and development expense for fiscal 2022 was $296.79M, a 23.32% decline from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 9 month as first filedResearch and Development Expense 12 monthResearch and Development Expense 12 month as first filed
2026-06-30$6.82M
10-Q · filed 2026-08-13
$14.39M
10-Q · filed 2026-08-13
$21.66M
derived: sum of 3 quarters · filed 2026-08-13
$22.86M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$7.57M
10-Q · filed 2026-05-12
$14.83M
derived: sum of 2 quarters · filed 2026-05-12
$16.04M
derived: sum of 3 quarters · filed 2026-05-12
$21.91M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$7.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
$8.48M
derived: sum of 2 quarters · filed 2026-03-16
$14.34M
derived: sum of 3 quarters · filed 2026-08-13
$23.52M
10-K · filed 2026-03-16
2025-09-30$1.21M
10-Q · filed 2025-11-10
$7.07M
derived: sum of 2 quarters · filed 2026-08-13
$16.25M
10-Q · filed 2025-11-10
$23.12M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$5.87M
10-Q · filed 2026-08-13
$15.04M
10-Q · filed 2026-08-13
$21.91M
derived: sum of 3 quarters · filed 2026-08-13
$41.88M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31$9.18M
10-Q · filed 2026-05-12
$16.04M
derived: sum of 2 quarters · filed 2026-05-12
$36.02M
derived: sum of 3 quarters · filed 2026-05-12
$68.38M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31$6.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
$26.84M
derived: sum of 2 quarters · filed 2026-03-16
$59.20M
derived: sum of 3 quarters · filed 2026-03-16
$95.69M
10-K · filed 2026-03-16
2024-09-30$19.97M
10-Q · filed 2025-11-10
$21.71M
10-Q · filed 2024-11-12
$52.33M
derived: sum of 2 quarters · filed 2025-11-10
$88.82M
10-Q · filed 2025-11-10
$94.21M
10-Q · filed 2024-11-12
$124.14M
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30$32.36M
10-Q · filed 2025-08-11
$34.11M
10-Q · filed 2024-08-06
$68.85M
10-Q · filed 2025-08-11
$72.50M
10-Q · filed 2024-08-06
$104.16M
derived: sum of 3 quarters · filed 2025-08-11
$165.36M
derived: sum of 4 quarters · filed 2025-08-11
2024-03-31$36.49M
10-Q · filed 2025-05-12
$38.39M
10-Q · filed 2024-05-06
$71.80M
derived: sum of 2 quarters · filed 2025-05-12
$133.00M
derived: sum of 3 quarters · filed 2025-05-12
$228.48M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31$35.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17
$96.51M
derived: sum of 2 quarters · filed 2025-03-17
$191.99M
derived: sum of 3 quarters · filed 2025-03-17
$266.47M
10-K · filed 2025-03-17
$282.86M
10-K · filed 2024-02-26
2023-09-30$61.19M
10-Q · filed 2024-11-12
$156.67M
derived: sum of 2 quarters · filed 2024-11-12
$231.16M
10-Q · filed 2024-11-12
$292.79M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$95.48M
10-Q · filed 2024-08-06
$169.96M
10-Q · filed 2024-08-06
$231.59M
derived: sum of 3 quarters · filed 2024-08-06
$306.77M
derived: sum of 4 quarters · filed 2024-08-06
2023-03-31$74.49M
10-Q · filed 2024-05-06
$136.11M
derived: sum of 2 quarters · filed 2024-05-06
$211.30M
derived: sum of 3 quarters · filed 2024-05-06
$282.26M
derived: sum of 4 quarters · filed 2024-05-06
2022-12-31$61.63M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26
$136.81M
derived: sum of 2 quarters · filed 2024-02-26
$207.77M
derived: sum of 3 quarters · filed 2024-02-26
$296.79M
10-K · filed 2024-02-26
2022-09-30$75.18M
10-Q · filed 2023-11-06
$146.15M
derived: sum of 2 quarters · filed 2023-11-06
$235.16M
10-Q · filed 2023-11-06
$349.08M
derived: sum of 4 quarters · filed 2024-02-26
2022-06-30$70.96M
10-Q · filed 2023-08-07
$159.98M
10-Q · filed 2023-08-07
$273.90M
derived: sum of 3 quarters · filed 2024-02-26
$349.78M
derived: sum of 4 quarters · filed 2024-02-26
2022-03-31$89.02M
10-Q · filed 2023-05-08
$202.94M
derived: sum of 2 quarters · filed 2024-02-26
$278.82M
derived: sum of 3 quarters · filed 2024-02-26
$401.38M
derived: sum of 4 quarters · filed 2024-02-26
2021-12-31$113.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26
$189.80M
derived: sum of 2 quarters · filed 2024-02-26
$312.37M
derived: sum of 3 quarters · filed 2024-02-26
$387.04M
10-K · filed 2024-02-26
2021-09-30$75.88M
10-Q · filed 2022-11-07
$198.45M
derived: sum of 2 quarters · filed 2022-11-07
$273.12M
10-Q · filed 2022-11-07
$351.25M
derived: sum of 4 quarters · filed 2023-02-27
2021-06-30$122.57M
10-Q · filed 2022-08-08
$197.24M
10-Q · filed 2022-08-08
$275.38M
derived: sum of 3 quarters · filed 2023-02-27
$333.85M
derived: sum of 4 quarters · filed 2023-02-27
2021-03-31$74.68M
10-Q · filed 2022-05-09
$152.81M
derived: sum of 2 quarters · filed 2023-02-27
$211.28M
derived: sum of 3 quarters · filed 2023-02-27
$272.70M
derived: sum of 4 quarters · filed 2023-02-27
2020-12-31$78.13M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27
$136.61M
derived: sum of 2 quarters · filed 2023-02-27
$198.02M
derived: sum of 3 quarters · filed 2023-02-27
$252.92M
10-K · filed 2023-02-27
2020-09-30$58.48M
10-Q · filed 2021-11-09
$119.89M
derived: sum of 2 quarters · filed 2021-11-09
$174.79M
10-Q · filed 2021-11-09
$231.59M
derived: sum of 4 quarters · filed 2022-03-04
2020-06-30$61.41M
10-Q · filed 2021-08-09
$116.31M
10-Q · filed 2021-08-09
$173.11M
derived: sum of 3 quarters · filed 2022-03-04
$223.08M
derived: sum of 4 quarters · filed 2022-03-04
2020-03-31$54.90M
10-Q · filed 2021-05-10
$111.70M
derived: sum of 2 quarters · filed 2022-03-04
$161.66M
derived: sum of 3 quarters · filed 2022-03-04
$213.67M
derived: sum of 4 quarters · filed 2022-03-04
2019-12-31$56.80M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-04
$106.76M
derived: sum of 2 quarters · filed 2022-03-04
$158.77M
derived: sum of 3 quarters · filed 2022-03-04
$209.26M
10-K/A · filed 2022-03-04
2019-09-30$49.96M
10-Q · filed 2020-11-05
$101.97M
derived: sum of 2 quarters · filed 2020-11-05
$152.47M
10-Q · filed 2020-11-05
$222.75M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30$52.01M
10-Q · filed 2020-08-06
$102.50M
10-Q · filed 2020-08-06
$172.79M
derived: sum of 3 quarters · filed 2021-03-01
$229.23M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31$50.50M
10-Q · filed 2020-05-07
$120.78M
derived: sum of 2 quarters · filed 2021-03-01
$177.22M
derived: sum of 3 quarters · filed 2021-03-01
$229.36M
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31$70.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
$126.73M
derived: sum of 2 quarters · filed 2021-03-01
$178.87M
derived: sum of 3 quarters · filed 2021-03-01
$235.84M
10-K · filed 2021-03-01
2018-09-30$56.44M
10-Q · filed 2019-11-12
$108.58M
derived: sum of 2 quarters · filed 2019-11-12
$165.56M
10-Q · filed 2019-11-12
$218.02M
derived: sum of 4 quarters · filed 2020-03-02
2018-06-30$52.14M
10-Q · filed 2019-08-08
$109.11M
10-Q · filed 2019-08-08
$161.58M
derived: sum of 3 quarters · filed 2020-03-02
$211.92M
derived: sum of 4 quarters · filed 2020-03-02
2018-03-31$56.97M
10-Q · filed 2019-05-09
$109.44M
derived: sum of 2 quarters · filed 2020-03-02
$159.78M
derived: sum of 3 quarters · filed 2020-03-02
$206.76M
derived: sum of 4 quarters · filed 2020-03-02
2017-12-31$52.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
$102.80M
derived: sum of 2 quarters · filed 2020-03-02
$149.78M
derived: sum of 3 quarters · filed 2020-03-02
$196.52M
10-K · filed 2020-03-02
2017-09-30$50.34M
10-Q · filed 2018-11-08
$97.32M
derived: sum of 2 quarters · filed 2018-11-08
$144.05M
10-Q · filed 2018-11-08
$194.66M
derived: sum of 4 quarters · filed 2019-02-27
2017-06-30$46.98M
10-Q · filed 2018-08-07
$93.71M
10-Q · filed 2018-08-07
$144.32M
derived: sum of 3 quarters · filed 2019-02-27
$184.88M
derived: sum of 4 quarters · filed 2019-02-27
2017-03-31$46.73M
10-Q · filed 2018-05-09
$97.34M
derived: sum of 2 quarters · filed 2019-02-27
$137.90M
derived: sum of 3 quarters · filed 2019-02-27
$190.29M
derived: sum of 4 quarters · filed 2019-02-27
2016-12-31$50.61M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27
$91.17M
derived: sum of 2 quarters · filed 2019-02-27
$143.56M
derived: sum of 3 quarters · filed 2019-02-27
$187.21M
10-K · filed 2019-02-27
2016-09-30$40.56M
10-Q · filed 2017-11-08
$92.95M
derived: sum of 2 quarters · filed 2017-11-08
$136.60M
10-Q · filed 2017-11-08
$196.52M
derived: sum of 4 quarters · filed 2018-02-27
2016-06-30$52.39M
10-Q · filed 2017-08-07
$96.04M
10-Q · filed 2017-08-07
$155.97M
derived: sum of 3 quarters · filed 2018-02-27
$208.04M
derived: sum of 4 quarters · filed 2018-02-27
2016-03-31$43.65M
10-Q · filed 2017-05-09
$103.57M
derived: sum of 2 quarters · filed 2018-02-27
$155.65M
derived: sum of 3 quarters · filed 2018-02-27
$207.20M
derived: sum of 4 quarters · filed 2018-02-27
2015-12-31$59.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
$112.00M
derived: sum of 2 quarters · filed 2018-02-27
$163.55M
derived: sum of 3 quarters · filed 2018-02-27
$214.09M
10-K · filed 2018-02-27
2015-09-30$52.07M
10-Q · filed 2016-11-08
$103.63M
derived: sum of 2 quarters · filed 2016-11-08
$154.16M
10-Q · filed 2016-11-08
$205.42M
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30$51.55M
10-Q · filed 2016-08-08
$102.09M
10-Q · filed 2016-08-08
$153.35M
derived: sum of 3 quarters · filed 2017-03-01
$193.97M
derived: sum of 4 quarters · filed 2017-03-01
2015-03-31$50.54M
10-Q · filed 2016-05-09
$101.80M
derived: sum of 2 quarters · filed 2017-03-01
$142.41M
derived: sum of 3 quarters · filed 2017-03-01
$175.68M
derived: sum of 4 quarters · filed 2017-03-01
2014-12-31$51.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
$91.88M
derived: sum of 2 quarters · filed 2017-03-01
$125.14M
derived: sum of 3 quarters · filed 2017-03-01
$150.79M
10-K · filed 2017-03-01
2014-09-30$40.62M
10-Q · filed 2015-11-12
$73.89M
derived: sum of 2 quarters · filed 2015-11-12
$99.54M
10-Q · filed 2015-11-12
2014-06-30$33.27M
10-Q · filed 2015-08-13
$58.92M
10-Q · filed 2015-08-13
2014-03-31$25.65M
10-Q · filed 2015-05-12
2013-12-31$85.71M
10-K · filed 2016-02-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
BeyondSpring Inc. (BYSI)United States$0.031B-10.95
AYTU BIOPHARMA, INC (AYTU)United States$0.025B-1.62
NANOVIRICIDES, INC. (NNVC)United States$0.031B
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
NextCure, Inc. (NXTC)United States$0.024B-0.15
TherapeuticsMD, Inc. (TXMD)United States$0.024B-117.87
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13